ApprovalTrail

Approval · Notice of Compliance 780 · 2002

CO RANITIDINE: Notice of Compliance 780

Issued August 13, 2002

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
780
Date
August 13, 2002
Company
Cobalt Pharmaceuticals IncorporatedToronto, Ontario, Canada
Product type
Prescription Pharmaceutical
Submission
Abbreviated New Drug Submission (ANDS)
Submission class
Admin
Reason
New manufacturer and product name
Therapeutic class
Histamine h2 receptor antagonist
Canadian reference product
ZANTAC (Glaxo Wellcome Inc.)

Products in this notice

BrandDINStatus today
CO RANITIDINE02246167—
CO RANITIDINE02246168—

Medicinal ingredients